Cantor Fitzgerald analyst Kristen Kluska raised the firm’s price target on Taysha Gene Therapies (TSHA) to $13 from $7 and keeps an Overweight rating on the shares. After having attended the IRSF Rett Syndrome Scientific Meeting and spent additional time with Taysha management, the firm has “very high conviction” that the TSHA-102 pivotal trial will succeed, the analyst tells investors. Following data and regulatory path updates, the firm is increasing its view of the odds of success for TSHA-102 to 70% from 35%, the analyst noted.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TSHA:
- Positive Outlook for Taysha Gene Therapies’ TSHA-102: Promising Clinical Data and Commercial Viability Justify Buy Rating
- Taysha Gene Therapies announces inducement grant under Nasdaq listing rule
- Taysha Gene Therapies announces updates from TSHA-102 clinical program
- Taysha Gene Therapies Approves Share Increase Amendment
- Taysha Gene Therapies price target raised to $11 from $9 at Canaccord